Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess improvement in renal impairment when switching from imatinib mesylate to second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia

Trial Profile

To assess improvement in renal impairment when switching from imatinib mesylate to second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top